Most of the clinical trials involving these inhibitors have demonstrated an association between response rate, outcomes and amount of tumour cell PD‐L1 expression (tumour proportion score; TPS), determined by immunohistochemistry (IHC). The gene discussed is CD274; the disease is neoplasm.